Approval of bimekizumab in the United States, an IL-17 A and F blocker with European approval for psoriatic arthritis. Dermatologists now have a range of choices for highly effective and safer options, both in biologics and orals.
Decisions, decisions! How neurons connect to shape our choices
Honeybees are more selective in their choices for nutrition than previously thought
Free will: Can neuroscience reveal if your choices are yours to make?
